Your daily dose of the clinical news you may have missed.

With the surge in demand and supply shortages, Michael Crotty, MD, discusses the future of GLP-1RA use in the treatment of obesity.

Research reveals that older age and lower aerobic fitness significantly increase the risk of arrhythmias, highlighting the need for early screening and fitness maintenance.

Your daily dose of the clinical news you may have missed.

Obesity medicine specialist Michael Crotty, MD, discusses the benefits of GLP-1 receptor agonist use in weight management and its impact on obesity-related comorbidities.

FDA clears MiniMed 780G for integration with Abbott’s Instinct sensor and approves its use in insulin-requiring T2D, expanding automated insulin delivery options.

Your daily dose of the clinical news you may have missed.

At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.

Caissa Troutman, member of the Obesity Medicine Association, emphasizes the importance of shared decision-making in overcoming barriers.

At ESC 2025, the STEER study showed semaglutide reduced risk of heart attack, stroke, or death by 57% vs tirzepatide in adults with obesity and cardiovascular disease, complementing prior trial data.